Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clarksterh who wrote (1336)	12/2/2004 3:40:03 PM
From: NeuroInvestment	Read Replies (1) of 1386

<<I'd agree, but Pharmos says in their published paper "dexanabinol treatment effects were not different between the two doses (data not shown).>> Clark--it seems to me it would have required a whopping dose-related contrast to make the comparison between 10 48mg pts and 20 150mg pts anywhere near statistical significance back in PhII. My vague recollection from conversations in 96-97 is that the preclinical data did show a dose-related response--so I am inclined to think that having everyone at 150mg will provide at least some added advantage. Harry NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next